F2G Ltd

About F2G Ltd

F2G is a company focused on developing novel therapeutics for rare, life-threatening fungal infections. Their mission is to provide more treatment options for patients, driven by a tenacious team, innovative science, and a patient-first ethos.

Products & Services

Novel Antifungals: Developing effective antifungal therapies to combat life-threatening fungal pathogens.

Specialties

Antifungal Drug Development Rare Fungal Infections Innovative Science for Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing Round T: - FT: Financing Round	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-09-12 FD: 2024-09-12	10 investors

Financing Round Latest

2024-09-12

$100.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lesley Fitton

Executive Director, Clinical Operations

F

Francesco Maria Lavino

Chief Executive Officer

R

Ralf Schmid

Chief Financial Officer

J

John H. Rex

Chief Medical Officer

M

Mike Birch

Chief Operating Officer

M

Mark Baglin

Chief Commercial Officer

View 28 more team members with Pro

Unlock Full Team Directory

Recent News

F2G Ltd Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised